Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
ARCH Venture Partners
Biotech
Bob Nelsen on megarounds, Altos and psychedelics
Arch's Bob Nelsen says if Xaira Therapeutics can realize its potential, then the $1 billion initial financing will likely be just the beginning.
Max Bayer
May 1, 2024 10:56am
New AI drug discovery powerhouse Xaira rises with $1B in funding
Apr 24, 2024 6:00am
Arch-backed obesity biotech launches with $290M
Apr 18, 2024 7:00am
Boundless Bio bumps IPO market back to life
Mar 6, 2024 5:20pm
VC investment in biopharma dropped nearly $7B in 2023: PitchBook
Mar 5, 2024 5:00am
Neumora files for IPO to fund phase 3 depression clinical trials
Aug 28, 2023 9:40am